Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1775194/000147793222003371/grvi_10q.htm
August 2022
August 2022
August 2022
August 2022
July 2022
July 2022
July 2022
May 2022
May 2022
April 2022
EXHIBIT 99.1
Grove, Inc. Announces Second Quarter Financial Results
$10.7 Million in Second Quarter Revenue, a 156% Increase Over Prior Year
$1.5 Million Adjusted EBITDA for Second Quarter
HENDERSON, NV / February 15, 2022 / Grove, Inc. (NASDAQ:GRVI) ("Grove" or the "Company"), a global innovator in hemp, health, and wellness, today announced financial results for the second quarter period ended December 31, 2021. Investors are encouraged to read the Company’s quarterly report on Form 10-Q which will be filed with the Securities and Exchange Commission (the “SEC”), contains additional information, and will be posted at https://groveinc.io/
.
Year to Date Financial Highlights
| · | Revenues rose to $19.1 million from $7.1 million, a 167% increase. |
| · | $0.04 basic earnings per share compared to loss of $0.06. |
| · | $2.9 million in adjusted EBITDA. |
| · | 103,750 shares of Grove common stock repurchased with cash flow from operations. |
Allan Marshall, Chief Executive Officer of Grove, stated, “Our team continues to perform and drive growth across all parts of our business, with a 169% increase year over year even with substantial headwinds. We face shortages and rising prices on all raw materials, employee shortages, higher wages, drastic increases in shipping cost across all parts of the business. However, we were able to maintain growth and profits offsetting increased costs with higher volumes and pricing power.
Our Upexi Amazon aggregation business launch is beginning to come together, and we are seeing multiple submissions a week from companies looking to be acquired. Our strong cash flow gives us great flexibility to expand the Brand aggregation business and become more active with acquisitions this year”
1 |
Liquidity and Capital Resources
|
| As of December 31, 2021 |
|
| As of June 30, 2021 |
| ||
Current assets |
| $ | 12,097,966 |
|
| $ | 18,293,083 |
|
Current liabilities |
| $ | 5,262,529 |
|
| $ | 5,819,161 |
|
Working capital |
| $ | 6,835,437 |
|
| $ | 12,473,922 |
|
Cash Flows
|
| Six Months Ended December 31, |
| |||||
|
| 2021 |
|
| 2020 |
| ||
Cash flows provided by (used in) operating activities |
| $ | 1,212,609 |
|
| $ | (669,321 | ) |
Cash flows (used in) provided by investing activities |
|
| (8,999,854 | ) |
|
| 241,785 |
|
Cash flows (used in) financing activities |
|
| (151,004 | ) |
|
| 738,000 |
|
Net decrease in cash during period |
| $ | (7,938,249 | ) |
| $ | 310,464 |
|
About Grove, Inc.
Grove, Inc. is a global innovator in hemp, health and wellness. The company has an array of in-house brands, and operates in multiple verticals including SaaS programmatic ad technology, and a wholly owned division dedicated to acquiring high growth e-commerce brands. The company sells to numerous consumer markets including the botanical, beauty, pet care, and functional foods sectors. It seeks to take advantage of an emerging worldwide trend in consumer health products selling through Amazon and E-commerce.
Company Contact
Andrew Norstrud
Email: investorinfo@cbd.io
Phone: (702) 332-5591
Investor Relations Contact
TraDigital IR
John McNamara
Email: john@tradigitalir.com
Phone: (917) 658-2602
Forward-Looking Statements
This press release contains statements that constitute "forward-looking statements," including with respect to the Company's business strategy, product development and industry trends. No assurance can be given that the offering will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
2 |
Use of Non-GAAP Financial Measures
The Company discloses and uses the above-mentioned non-GAAP financial measures internally as a supplement to GAAP financial information to evaluate its operating performance, for financial planning purposes, to establish operational goals, for compensation plans, to measure debt service capability, for capital expenditure planning and to determine working capital needs and believes that these are useful financial measures also used by investors. Non-GAAP adjusted EBITDA is defined as GAAP net income or net loss before interest, taxes, depreciation and amortization (EBITDA) adjusted for the non-cash stock compensation and stock option expense, acquisition, integration & restructuring expenses, charges and gains or losses from extinguishment of debt and other non-cash items. Non-GAAP EBITDA and non-GAAP adjusted EBITDA are not terms defined by GAAP and, as a result, the Company’s measure of non-GAAP EBITDA and non-GAAP adjusted EBITDA might not be comparable to similarly titled measures used by other companies. Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position, or cash flow that either excludes or includes amounts that are not normally included in the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP financial measures discussed above, however, should be considered in addition to, and not as a substitute for, or superior to net income or net loss as reported for GAAP on the Consolidated Statements of Operations, cash and cash flows on the Consolidated Statement of Cash Flows or other measures of financial performance prepared in accordance with GAAP, and as reflected on the Company’s financial statements prepared in accordance with GAAP. These non-GAAP financial measures are not a substitute for or presented in lieu of financial measures provided by GAAP and all measures and disclosures of financial information pursuant to GAAP should be read to obtain a comprehensive and thorough understanding of the Company’s financial results. The reconciliations of non-GAAP EBITDA and non-GAAP adjusted EBITDA to GAAP operating income (loss) and/or GAAP net income (net loss) referred to in the highlights or elsewhere are provided in the schedules that are a part of this document.
3 |
CONDENSED CONSOLDIATED BALANCE SHEETS (UNAUDITED) | ||||||||
|
|
|
|
|
|
| ||
|
| December 31, |
|
| June 30, |
| ||
|
| 2021 |
|
| 2021 |
| ||
|
|
|
|
|
|
| ||
ASSETS |
|
|
|
|
|
| ||
Current assets |
|
|
|
|
|
| ||
Cash |
| $ | 6,595,962 |
|
| $ | 14,534,211 |
|
Accounts receivable, net of allowance for doubtful accounts of $92,500 and $57,500, respectively |
|
| 1,247,218 |
|
|
| 1,277,662 |
|
Inventory |
|
| 3,681,428 |
|
|
| 2,094,952 |
|
Prepaid expenses and other receivables |
|
| 573,358 |
|
|
| 386,258 |
|
Total current assets |
|
| 12,097,966 |
|
|
| 18,293,083 |
|
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
| 7440,332 |
|
|
| 2,832,400 |
|
Intangible assets, net |
|
| 5,189,234 |
|
|
| 1,845,166 |
|
Goodwill |
|
| 8,533,923 |
|
|
| 2,413,813 |
|
Deferred tax asset |
|
| 1,225,917 |
|
|
| 1,403,591 |
|
Other assets |
|
| 69,068 |
|
|
| 49,068 |
|
Right-of-use asset |
|
| 648,626 |
|
|
| 417,443 |
|
Total other assets |
|
| 23,107,100 |
|
|
| 8,961,481 |
|
|
|
|
|
|
|
|
|
|
Total assets |
| $ | 35,205,066 |
|
| $ | 27,254,564 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
| $ | 895,846 |
|
| $ | 1,604,723 |
|
Accrued compensation |
|
| 679,000 |
|
|
| 1,020,936 |
|
Deferred revenue |
|
| 959,329 |
|
|
| 485,973 |
|
Accrued liabilities |
|
| 873,585 |
|
|
| 296,021 |
|
Acquisition payable |
|
| 600,000 |
|
|
| 1,764,876 |
|
Current portion of notes payable |
|
| 1,006,197 |
|
|
| 447,100 |
|
Current portion of operating lease payable |
|
| 248,572 |
|
|
| 199,532 |
|
Total current liabilities |
|
| 5,262,529 |
|
|
| 5,819,161 |
|
|
|
|
|
|
|
|
|
|
Operating lease payable, net of current portion |
|
| 395,085 |
|
|
| 217,430 |
|
Notes payable, net of current portion |
|
| 26,766 |
|
|
| - |
|
Total long-term liabilities |
|
| 421,851 |
|
|
| 217,430 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies |
|
| - |
|
|
| - |
|
|
|
|
|
|
|
|
|
|
Stockholders' equity |
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value, 100,000,000 shares authorized, and 500,000 and 500,000 shares issued and outstanding, respectively |
|
| 500 |
|
|
| 500 |
|
Common stock, $0.001 par value, 100,000,000 shares authorized, and 15,711,339 and 15,262,394 shares issued and outstanding, respectively |
|
| 16,378 |
|
|
| 15,262 |
|
Additional paid in capital |
|
| 33,097,300 |
|
|
| 25,372,247 |
|
Accumulated deficit |
|
| (3,593,492 | ) |
|
| (4,170,036 | ) |
Total stockholders' equity |
|
| 29,520,686 |
|
|
| 21,217,973 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders' equity |
| $ | 35,205,066 |
|
| $ | 27,254,564 |
|
4 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) |
|
| Three Month's Ended December 31, |
|
| Six Month's Ended December 31, |
| ||||||||||
|
| 2021 |
|
| 2020 |
|
| 2021 |
|
| 2020 |
| ||||
Revenue |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Revenue |
|
| 10,666,781 |
|
|
| 4,164,894 |
|
|
| 19,116,535 |
|
|
| 7,102,336 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of Revenue |
|
| 3,956,358 |
|
|
| 2,234,259 |
|
|
| 7,023,734 |
|
|
| 3,853,467 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
| 6,710,423 |
|
|
| 1,930,635 |
|
|
| 12,092,801 |
|
|
| 3,248,869 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing |
|
| 1,852,118 |
|
|
| 459,446 |
|
|
| 3,363,805 |
|
|
| 824,704 |
|
General and administrative expenses |
|
| 4,740,705 |
|
|
| 1,714,484 |
|
|
| 8,175,853 |
|
|
| 3,427,546 |
|
|
|
| 6,592,823 |
|
|
| 2,173,930 |
|
|
| 11,539,658 |
|
|
| 4,252,250 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations |
|
| 117,600 |
|
|
| (243,295 | ) |
|
| 553,143 |
|
|
| (1,003,381 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense), net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest (expense) income, net |
|
| (26,605 | ) |
|
| (42,049 | ) |
|
| (42,561 | ) |
|
| (84,740 | ) |
Other (expense) income, net |
|
| - |
|
|
| 4 |
|
|
| - |
|
|
| (6,292 | ) |
Settlement of cancelled lease |
|
| - |
|
|
| 387,860 |
|
|
| - |
|
|
| 387,860 |
|
Gain on SBA PPP loan extinguishment |
|
| - |
|
|
| - |
|
|
| 300,995 |
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense), net |
|
| (26,605 | ) |
|
| 345,815 |
|
|
| 258,434 |
|
|
| 296,828 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income tax |
|
| 90,995 |
|
|
| 102,520 |
|
|
| 811,577 |
|
|
| (706,553 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense |
|
| (26,162 | ) |
|
| - |
|
|
| (235,033 | ) |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
| 64,833 |
|
|
| 102,520 |
|
|
| 576,544 |
|
|
| (706,553 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic income (loss) per share |
| $ | 0.00 |
|
| $ | 0.01 |
|
| $ | 0.04 |
|
| $ | (0.06 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted income (loss) per share |
| $ | 0.00 |
|
| $ | 0.01 |
|
| $ | 0.03 |
|
| $ | (0.06 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding |
|
| 16,378,006 |
|
|
| 13,455,013 |
|
|
| 15,915,154 |
|
|
| 11,830,013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fully diluted weighted average shares outstanding |
|
| 17,685,717 |
|
|
| 13,455,013 |
|
|
| 17,453,141 |
|
|
| 11,830,013 |
|
5 |
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1775194/000147793222003371/grvi_10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Grove, Inc..
Grove, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Rating
Learn More![]()
This improved gross margin was from the increase in sales using more of the Company's manufacturing capacity, the increased use of machines in the manufacturing and packaging process and the higher margins in direct-to-consumer sales.
This improved gross margin was from the increase in sales using more of the Company's manufacturing capacity, the increased use of machines in the manufacturing and packaging process and the higher margins in direct-to-consumer sales.
These costs were offset by approximate decreases of $349,200 general and administrative costs as the Company benefited from the consolidation of facilities and administrative personnel.
The decrease in net income is primarily related to the above-mentioned changes, including approximately $1,129,100 of non-cash expenses related to share-based compensation and amortization of acquired identifiable intangible assets.
Liquidity and Capital Resources Working Capital Cash Flows At March 31, 2022, the Company had cash of $4,502,986 a decrease of $10,031,225 from June 30, 2021.
The decrease of interest expense...Read more
The use of cash for...Read more
During the nine months ended...Read more
During the nine months ended...Read more
Operating expenses increased by $3,765,897...Read more
22 Operating expenses increased by...Read more
Approximately $2,083,900 was from the...Read more
Approximately $5,114,900 was from the...Read more
Three Months Ended March 31,...Read more
Nine Months Ended March 31,...Read more
Gross margin improved by approximately...Read more
Gross margin improved by approximately...Read more
During the nine months ended...Read more
Approximately $4,121,100 of the increase...Read more
There is significant uncertainty around...Read more
There is significant uncertainty around...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Grove, Inc. provided additional information to their SEC Filing as exhibits
Ticker: GRVI
CIK: 1775194
Form Type: 10-Q Quarterly Report
Accession Number: 0001477932-22-003371
Submitted to the SEC: Mon May 16 2022 9:25:56 AM EST
Accepted by the SEC: Mon May 16 2022
Period: Thursday, March 31, 2022
Industry: Medicinal Chemicals And Botanical Products